LaFleur & Godfrey LLC Sells 1,649 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 22nd, 2023

LaFleur & Godfrey LLC decreased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 110,886 shares of the company’s stock after selling 1,649 shares during the period. Johnson & Johnson makes up 3.3% of LaFleur & Godfrey LLC’s holdings, making the stock its 6th biggest holding. LaFleur & Godfrey LLC’s holdings in Johnson & Johnson were worth $19,588,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Price T Rowe Associates Inc. MD raised its holdings in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC increased its position in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. GQG Partners LLC increased its position in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $153.89 on Wednesday. Johnson & Johnson has a twelve month low of $150.71 and a twelve month high of $186.69. The firm has a 50 day moving average price of $161.11 and a 200-day moving average price of $167.82. The company has a market capitalization of $400.77 billion, a P/E ratio of 22.83, a P/E/G ratio of 2.63 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. Johnson & Johnson’s revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.13 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s payout ratio is currently 67.06%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. SVB Leerink decreased their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $174.73.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.